日水製薬(株)の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|---|---|---|
東証PRM | 医薬品 | 4550/E00971 | Nissui Pharmaceutical Co., Ltd |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|---|---|---|---|---|---|---|---|---|
2017/06/02 | 日証協 | 41,700株 | +59.77% | 57,000株 | +21.28% | 135,048株 | -2.1% | 5,700株 | +128% |
2017/05/26 | 日証協 | 26,100株 | -28.67% | 47,000株 | -2.67% | 137,948株 | +0.25% | 2,500株 | -79.49% |
2017/05/19 | 日証協 | 36,589株 | +167.07% | 48,289株 | +382.89% | 137,598株 | +5.24% | 12,192株 | +238.67% |
2017/05/12 | 日証協 | 13,700株 | +41.24% | 10,000株 | +269% | 130,745株 | +1.62% | 3,600株 | +49.38% |
2017/05/02 | 日証協 | 9,700株 | +1.04% | 2,710株 | +351.67% | 128,655株 | +0.4% | 2,410株 | +26.18% |
2017/04/28 | 日証協 | 9,600株 | 0% | 600株 | -87.21% | 128,145株 | -0.08% | 1,910株 | -48.39% |
2017/04/21 | 日証協 | 9,600株 | +3.23% | 4,690株 | -6.2% | 128,245株 | -2.95% | 3,701株 | -33.91% |
2017/04/14 | 日証協 | 9,300株 | +6.9% | 5,000株 | -21.88% | 132,144株 | +1.93% | 5,600株 | -50.88% |
2017/04/07 | 日証協 | 8,700株 | -71.84% | 6,400株 | +120.69% | 129,644株 | +150.22% | 11,400株 | -93.39% |
2017/03/31 | 日証協 | 30,900株 | +11.15% | 2,900株 | -30.95% | 51,813株 | -63.34% | 172,354株 | +1733.55% |
2017/03/24 | 日証協 | 27,800株 | +9.02% | 4,200株 | +162.5% | 141,343株 | -4.53% | 9,400株 | +95.83% |
2017/03/17 | 日証協 | 25,500株 | +129.73% | 1,600株 | -88.97% | 148,051株 | +10.2% | 4,800株 | -69.64% |
2017/03/10 | 日証協 | 11,100株 | +4.72% | 14,500株 | +866.67% | 134,351株 | +1.13% | 15,808株 | +731.56% |
2017/03/03 | 日証協 | 10,600株 | +23.26% | 1,500株 | +15.38% | 132,851株 | +3.59% | 1,901株 | +18.81% |
2017/02/24 | 日証協 | 8,600株 | +2.38% | 1,300株 | 0% | 128,251株 | -4.47% | 1,600株 | -44.83% |
2017/02/17 | 日証協 | 8,400株 | -25% | 1,300株 | +8.33% | 134,251株 | -1.9% | 2,900株 | +222.22% |
2017/02/10 | 日証協 | 11,200株 | -0.88% | 1,200株 | -61.29% | 136,851株 | -1.51% | 900株 | -76.98% |
2017/02/03 | 日証協 | 11,300株 | -13.08% | 3,100株 | +3.33% | 138,951株 | +2.06% | 3,909株 | +62.88% |
2017/01/27 | 日証協 | 13,000株 | +4% | 3,000株 | +42.86% | 136,142株 | +0.52% | 2,400株 | -50% |
※株式分割は考慮していませんのでご注意ください。